Morphosys in Transformative Deal With Celgene, Morphs Into FIBCO
This article was originally published in The Pink Sheet Daily
Executive Summary
Morphosys and Celgene have agreed to jointly develop MOR202 for multiple myeloma, and to co-promote it in Europe. The deal allows Morphosys for the first time to participate in the commercialization of one of its products and decisively validates commercial interest in one of the industry’s hot oncology targets